Document is current
Any future updates will be listed below
-
Authors
Sverzhinsky, Aleksandr https://orcid.org/0000-0003-1405-925X
Xue, Huijun
Langelier, Marie-France https://orcid.org/0000-0001-9815-1840
Muniz Corrêa, Marcelo V.
Del Mundo, Joshua
Classen, Scott https://orcid.org/0000-0002-5500-9104
Hammel, Michal https://orcid.org/0000-0002-5610-9289
Rothenberg, Eli https://orcid.org/0000-0002-1382-1380
Pascal, John M. https://orcid.org/0000-0002-2714-4317
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (PJT374609)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA92584)
- License Information
-
More Information
Article History
Received: 8 January 2025
Accepted: 30 January 2026
First Online: 16 February 2026
Competing interests
: J.M.P. is a co-founder of Hysplex with interests in PARP inhibitor development. The remaining authors declare no competing interests.
